News

Oval Medical Technologies signs key agreement with leading global pharmaceutical company

14 May 2012

May 14th, 2012 – Oval Medical Technologies Ltd. (“Oval”), the company developing the next generation of autoinjectors, today announced that they have entered into an agreement with a top ten global pharmaceutical company to evaluate one of their leading prescription drugs in Oval’s novel autoinjector technology. Under the terms of Agreement, the pharmaceutical company has…

More...

Oval Medical collaborates with the Cambridge University MBA Venture Project

06 February 2012

6th February 2012 – Cambridge-based Oval Medical Technologies Limited (“Oval Medical”) has recently collaborated on the Cambridge Venture Project (CVP), part of the MBA programme at the Judge Business School, University of Cambridge. Oval Medical has developed a unique autoinjector and syringe technology that will allow patients of different ages and from various therapeutic areas…

More...

Oval Medical expands with two new hires

18 July 2011

Monday, 18 July 2011 -The autoinjector development company Oval Medical Technologies ltd, has today announced further expansion with two new appointments of a Programme Manager and a Design Engineer. Alison Kwok joins the company in the capacity of Programme Manager from Owen Mumford where she held the post of Technical Project Manager for the past…

More...

Oval signs two feasibility deals with pharmaceutical companies

11 April 2011

11th April 2011 – Oval Medical Technologies Ltd., the company developing the next generation of autoinjector technology, announced today that they have entered into two deals with pharmaceutical companies who are putting Oval’s primary drug containment technology through feasibility trials. Oval’s CEO Matthew Young has said, ‘These two deals have been signed at a key…

More...

Next generation autoinjector shows clear superiority

10 January 2011

10th January 2011 – Oval Medical Technologies Ltd., the Cambridge based autoinjector company today announced results from two user studies in which Oval’s novel, proprietary autoinjector clearly demonstrated superiority compared with two well-known autoinjector devices currently on the market. The Oval next generation autoinjector is designed to be smaller, easier and safer to use than…

More...

Catherine Beech interviewed by the Cambridge Evening News

08 August 2010

Dr. Catherine Beech talks with Business Editor Jenny Chapman. ‘He’s one of those people who can see a better way of doing things, to make them more useful,” says Dr Catherine Beech, talking about Matthew Young, founder of one of the city’s hottest new companies, Oval Medical Technologies.’

More...

Oval Medical featured in ONdrugDELIVERY

01 August 2010

Oval Medical Technologies Limited is based in Cambridge and has broad expertise in design and development of drug delivery devices focusing on vials, prefilled syringes and autoinjectors. The company was born out of what it saw as a need for radical innovation in the design of autoinjectors.

More...

Three new employees appointed

27 July 2010

27th July 2010 – Today, Oval Medical is pleased to announce that the on-going success of developing its revolutionary autoinjector and syringe technologies, has lead to the company’s second expansion less than a year after the company was established.</p> As of July 2010, three new members have joined the team adopting a variety of roles…

More...

Business Weekly Feature: Interview with Matthew Young, Founder of Oval Medical Technologies

18 June 2010

Oval Medical Technologies Limited is based in Cambridge and has broad expertise in design and development of drug delivery devices focusing on vials, prefilled syringes and autoinjectors. The company was born out of what it saw as a need for radical innovation in the design of autoinjectors.

More...

Oval Medical signs a technology assessment contract with a pharmaceutical partner

12 February 2010

February 12th, 2013 – Oval Medical Technologies Ltd.(“Oval”),  announces that it has signed a further technology assessment contract with a pharmaceutical partner. The drug under investigation is for the treatment of severe infections in patients with chronic lung disease and is expected to be self-injected in a clinical or home setting. The agreement includes a…

More...

Events

Pharmapack 2020

February 5, 2020 - February 6, 2020
Paris Expo, Porte de Versailles

Bio-Europe Spring 2020

March 23, 2020 - March 25, 2020
Paris Expo, Porte de Versailles

Bio 2020

June 8, 2020 - June 11, 2020
San Diego
input search string and hit enter